AIDOT Inc. (CEO: Jaehun Jung), a medical AI solution company, announced that it participated in the 2026 Integrated Obstetrics and Gynecology Conference and Training Course, held from April 25 to 26 at the Busan Lotte Hotel, where it showcased its AI-powered cervical cancer diagnostic support solution, Cerviray AI.

Cerviray AI is Korea’s only AI cervical cancer solution designated as an innovative medical device by the Ministry of Trade, Industry and Energy (MOTIE).

The solution has received MFDS certification for its technology that automatically detects suspected lesion areas immediately after image capture and provides four-stage analysis results.

In particular, medical professionals from secondary and tertiary hospitals gave positive feedback, noting that Cerviray AI “visually marks suspected lesion areas before biopsy, significantly improving diagnostic accuracy and efficiency.”

Beyond simply distinguishing between normal and abnormal findings, Cerviray AI supports lesion location detection and CIN-stage analysis, which is recognized as a world-first differentiated capability.

AIDOT has also completed MFDS registration for the ultra-lightweight version of its AI model, further expanding the solution’s potential use in domestic clinical settings based on its verified technology.

An AIDOT representative stated, “Through this conference, we directly demonstrated Cerviray AI’s unique clinical utility and performance to medical professionals. We will continue to expand touchpoints with clinicians and establish Cerviray AI as the standard AI solution in Korea’s cervical cancer screening market.”

Key features of Cerviray AI include on-device AI analysis with no internet connection required, MFDS Class III approval, four-stage lesion classification (Normal / CIN1 / CIN2-3 / CIN3+), detailed lesion detection box display, and designation as Korea’s only MOTIE Innovative Product among AI cervical cancer diagnostic devices.

Korea Economic TV / 2026-04-27 / Yang Jaejun, Deputy Managing Editor